It is likely that the assessment of chemicals for mutagenicity will soon become a widespread practice, and a large number of different screening procedures have been proposed. The subjection of every new chemical to be released into the environment to every available test is clearly an impossible task, and it is necessary for an understanding of priorities in terms of risk and benefit to be built into any approach. The present paper represents an attempt to frame a protocol for the assessment of new compounds that is concerned not with the details of individual tests but rather with the questions these tests should be designed to answer and to the evaluation of the answers obtained. It is obviously inherent in such an approach that a similar assessment must be made of chemicals already in the environment, but that is not the purpose of the present article.
Genetic hazards (with the exception of nondisjunction and some other chromosomal abnormalities) are very different from toxic hazards, in that there is little or no likelihood of any feedback from human epidemiological data. Toxicologists have stressed (1) There is likely to be a hazy line between such special mutagens and general mutagens and some knowledge of the mechanism of mutagenesis will usually be required in order to be able to judge whether man is likely to be affected by a particular agent. The greater value of logical and painstaking in-depth research over routine testing is as obvious here as it is with the assessment of non-genetic toxicological hazards (2) .
The second general principle is that the extent and rigor of the screening procedures should be related to the extent to which man is likely to be exposed to the agent. Thus a food additive for widespread use would need a great deal more attention than a short-lived no-residue pesticide designed solely for professional horticultural use.
The third general principle is that mutagenic substances may be used if the benefits are judged to be great enough to outweigh the hazards and if appropriate controls are exercised. The precedent for this has already been established by ionizing radiation.
Three-Tier Framework
The proposed framework consists of a three-tiered evaluation procedure ( Fig. 1 The important feature that distinguishes the third from the first two tiers is that whereas the latter comprise tests for the detection of mutagenic activity, the evaluation tier requires that a quantitative estimate be made of the mutational risk to man. This may be an unusual approach to some who have viewed this problem solely from a toxicological angle, but it is a necessary exercise simply because with mutational risks we are concerned with relatively rare events in future populations rather than with observable effects in individual men and women. One cannot assume that a "noeffect" dose level exists for mutagens.
The third tier assessors would be charged with designing the experiments for evaluating the mutational risk. These experiments should take into account the properties and proposed applications of each individual compound. In considering possible experiments, I shall confine my attention to gene mutations only although comparable procedures could be devised for chromosomal damage. In principle, the specific locus test in the mouse (15) is a very suitable test that has been successfully used with ionizing radiation. Unfortunately, except in rare cases, the doses of mutagenic compounds to be used in practice would be below the detection level of the test (a level which is in fact determined by the enormous cost of the method). Using higher doses one might be able to obtain values which could be extrapolated to lower doses, but it would be a very laborious business to obtain enough mutants to have any confidence in the extrapolation. I would like to make it very clear that negative results in the specific locus test (or the HMA test) do not, because of the low sensitivity of these tests, automatically signify the absence of a hazard for man. A fairly extensive specific locus experiment may well not detect significant mutagenesis from a single-dose of 50 rads of gamma radiation, and yet some application resulting in a yearly dose to man 1000-fold smaller than this would be regarded with great concern by the International Commission on Radiological Protection.
The HMA might be used if the cellular system were mammalian and if enough different doses could be used to enable a dose response -curve to be obtained. Two Figure 2 ). It is, however, possible that these problems may be overcome at least with some substances.
These disadvantages would not exist if the dose response curve were determined for mammalian cells in vitro (Fig. 3) ideally for a number of different loci and for human as well as rodent cells. Particular attention should be paid to the low-dose region of the dose response curve and, of course, any metabolites active in vivo would also need to be studied. It Obviously the authorized use of any known mutagen should be accompanied by such control procedures as may be required to ensure that all unnecessary exposure is eliminated and that the permitted levels are not being exceeded.
Concluding Remarks
The assessors' task will be frought with difficulties (16) . One of the more fundamental problems will be the determination of an overall maximum acceptable risk for the human population. Geneticists are far from being agreed on the quantitative aspect of the deleterious consequences of an increased rate of gene mutation and the whole field has developed enormously since the levels for ionizing radiation were set. One thing is patently clear: it is logically absurd and practically foolish to try to deal with genetic hazards from chemicals and from radiations in isolation. Ultimately, we should look forward to the establishment of an Environmental Genetic Hazards Commission to consider environmental genetic damage as a whole, in contrast to the piecemeal assessment of food additives, drugs, pesticides, radiations etc., that exists at present (if it exists at all).
